R M Lane

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi request reprint A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction; incidence, possible aetiology and implications for management
    R M Lane
    Pfizer Inc, New York, NY 10017, USA
    J Psychopharmacol 11:72-82. 1997
  2. ncbi request reprint SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment
    R M Lane
    Pfizer Inc, New York, NY 10017, USA
    J Psychopharmacol 12:192-214. 1998
  3. ncbi request reprint A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression
    J Søgaard
    Pfizer Inc, New York, NY 10017 5755, USA
    J Psychopharmacol 13:406-14. 1999
  4. ncbi request reprint Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment
    J R Walker
    Sertraline Social Phobia Study Group, Pfizer Inc, New York, New York, USA
    J Clin Psychopharmacol 20:636-44. 2000

Collaborators

  • J R Walker
  • J Søgaard
  • R T Reesal
  • P Latimer
  • A V Ravindran
  • K Behnke
  • B Nielsen
  • P E Christiansen
  • D P Goodwin

Detail Information

Publications4

  1. ncbi request reprint A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction; incidence, possible aetiology and implications for management
    R M Lane
    Pfizer Inc, New York, NY 10017, USA
    J Psychopharmacol 11:72-82. 1997
    ....
  2. ncbi request reprint SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment
    R M Lane
    Pfizer Inc, New York, NY 10017, USA
    J Psychopharmacol 12:192-214. 1998
    ..It is important that the rare occurrence of EPS in patients receiving SSRIs does not preclude their use in Parkinson's disease where their potentially significant role requires more systematic evaluation...
  3. ncbi request reprint A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression
    J Søgaard
    Pfizer Inc, New York, NY 10017 5755, USA
    J Psychopharmacol 13:406-14. 1999
    ..There were no other significant differences between treatment groups. Overall, both medications were well tolerated. In this study, both sertraline and moclobemide improved the symptoms of atypical depression...
  4. ncbi request reprint Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment
    J R Walker
    Sertraline Social Phobia Study Group, Pfizer Inc, New York, New York, USA
    J Clin Psychopharmacol 20:636-44. 2000
    ..Future research should assess whether improvements may be maintained or further increased by longer periods of treatment or through the addition of cognitive-behavioral techniques...